Antibody-drug conjugates (ADCs) represent a significant advancement in cancer treatment by combining the targeting ability of monoclonal antibodies with cytotoxic drugs.

Two-dimensional (2D) cell cultures have been extensively used as tools to predict preclinical outcomes before proceeding to expensive animal studies despite their limited success in replicating in vivo studies.

Model growth kinetics and response to multiple treatment types were evaluated for syngeneic Renca murine renal cell carcinoma. Immune profile characterization was performed via flow cytometry to assess changes within the immune cell subsets following different treatment types and from control tumors at different tumor volumes.

The development of a 30-color immunophenotyping panel using the Cytek Aurora™ Spectral Flow Cytometer has enabled detailed profiling of T cell, NK and B cell subsets, along with their functional states.

Analysis of UGT1A1 pharmacogenomic profiles in 564 cancer patients revealed that 53% had reduced metabolizer status, potentially increasing toxicity or reducing efficacy of UGT1A1-metabolized drugs.

PacBio amplicon sequencing was used as an orthogonal method to confirm the performance of Labcorp Pan-Heme NGS (LPH) panel to detect somatic variants in hematologic malignancies across 141 clinically relevant genes.

Analysis of 146 Japanese pancreatic adenocarcinoma (PC) patients using exome-based cancer genomic profiling (CGP) identified somatic mutations with KRAS,TP53, SMAD4 and CDKN2A being the most frequent.

Analysis of syngeneic mouse models using human-validated immune gene expression (iGEX) measurements to assess tumor immune microenvironments and treatment responses demonstrated that in vivo tumor fragments exhibited higher immune activity than in vitro tumor cell lines and closely resembled iGEX measures in human tumors.